Precision Medicine has been a central theme in healthcare and public policy over the past decade. Its goal is clear: to leverage risk prediction and accurate diagnostics so that clinicians can deliver targeted treatments, minimize adverse effects, and improve long-term outcomes—ultimately enhancing healthcare quality and preserving quality of life.
About Mayo Clinic Laboratories
Founded in 1864, Mayo Clinic is one of the world’s most prestigious medical centers, headquartered in Rochester, Minnesota, and consistently ranked among the top hospitals in the U.S. News & World Report.
Its Department of Laboratory Medicine and Pathology houses one of the largest diagnostic teams in the world, spanning clinical pathology, molecular diagnostics, oncology, neuroscience, immunology, and rare diseases. Its affiliated Mayo Clinic Laboratories serves as a leading global referral laboratory, processing more than 25 million tests annually for over 4,500 healthcare institutions across 65 countries.
Collaboration with Taiwan
Mayo Clinic has long maintained active partnerships with Taiwan’s medical and biotech sectors, particularly in oncology, neurology, and cell therapy. In neuroimmunology diagnostics, Mayo Clinic Laboratories is recognized internationally for its accuracy and interpretative expertise.
Through a stable collaboration with Taiwan, clinical samples can be sent directly to the United States for analysis—without third-party transfer—ensuring shorter turnaround times, secure handling, and reliable reporting. This enables physicians and patients in Taiwan to access the same advanced diagnostic resources available in the U.S.
Rare Disease Testing, International Credibility, and Innovation
While Taiwan’s laboratories already provide comprehensive and advanced diagnostics, Mayo Clinic Laboratories offers an unmatched portfolio of over 3,500 specialized assays. These include rare diseases, uncommon autoimmune conditions, and neurodegenerative disorders such as limbic encephalitis and Alzheimer’s biomarkers.
For tests with low local demand or insufficient case numbers, developing in-house capabilities may be costly or impractical. Direct access to Mayo Clinic Laboratories provides an immediate solution. Importantly, Mayo is also a global driver of diagnostic innovation: many cutting-edge methods—such as neural antibody panels and next-generation sequencing—were first developed at Mayo and have since become gold standards in international clinical guidelines.
Focus on Neuroimmunology
The Uni-Pharma Molecular Biology Laboratory has a long-standing focus on neuroimmunological disorders, including autoimmune encephalitis, demyelinating diseases, and neurodegeneration. These conditions often require highly specific and sensitive testing methods. Mayo Clinic’s innovations—such as the MOG antibody Cell-Based Assay (CBA) and Live Cell platforms—have proven invaluable in distinguishing between diagnostically challenging conditions like NMOSD and MOGAD.
Through this collaboration, physicians in Taiwan gain access to more than 3,500 advanced tests, providing greater diagnostic confidence in complex cases. Patients benefit by receiving internationally aligned standards of care in the shortest possible time.
